Back to top
more

Novo Nordisk (NVO)

(Delayed Data from NYSE)

$111.94 USD

111.94
4,553,843

-0.01 (-0.01%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $111.97 +0.03 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Novo Nordisk (NVO) Catches Eye: Stock Jumps 7.2%

Novo Nordisk (NVO) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Novo Nordisk's (NVO) Q3 Earnings Beat Estimates, Sales Miss

Novo Nordisk (NVO) misses earnings and sales estimates in the third quarter of 2020.

SNY or NVO: Which Is the Better Value Stock Right Now?

SNY vs. NVO: Which Stock Is the Better Value Option?

Sheraz Mian headshot

Q3 Earnings Scorecard and Top Research Reports for Apple, PepsiCo & McDonald's

Today's Research Daily features Q3 earnings season scorecard and new research reports on Apple (AAPL), PepsiCo (PEP) and McDonald's (MCD) and others.

Kinjel Shah headshot

Pharma Stock Roundup: LLY, AZN, PFE, GSK Progress on Coronavirus Programs

Lilly (LLY), Pfizer (PFE) and AstraZeneca (AZN) provide updates on their coronavirus vaccine/treatment programs.

Novo Nordisk Raises Sales & Operating Profit Outlook for 2020

Novo Nordisk (NVO) raises 2020 sales and operating profit outlook at constant exchange rates.

The Zacks Analyst Blog Highlights: JPM, PYPL, NVO, RHHBY and TM

The Zacks Analyst Blog Highlights: JPM, PYPL, NVO, RHHBY and TM

SNY vs. NVO: Which Stock Should Value Investors Buy Now?

SNY vs. NVO: Which Stock Is the Better Value Option?

Sheraz Mian headshot

Top Analyst Reports for JPMorgan, PayPal & Novo Nordisk

Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase (JPM), PayPal (PYPL) and Novo Nordisk (NVO).

Lilly Drug Gets Fast Track to Improve Heart Attack Outcome

Lilly's (LLY) EMPACT-MI study is part of Jardiance's ENPOWER clinical program, which is studying the impact of Jardiance on major clinical cardiovascular and renal outcomes in a spectrum of cardio-renal-metabolic conditions.

The Zacks Analyst Blog Highlights: DIS, NVO, BHP, AVGO and LLY

The Zacks Analyst Blog Highlights: DIS, NVO, BHP, AVGO and LLY

Sheraz Mian headshot

Top Research Reports for Disney, Novo Nordisk & BHP

Today's Research Daily features new research reports on 16 major stocks, including Disney (DIS), Novo Nordisk (NVO) and BHP Group (BHP).

Lilly (LLY) Gets FDA Approval for Higher Doses of Trulicity

Lilly's (LLY) higher doses of Trulicity led to superior reductions in blood glucose level and weight in type II diabetes patients compared to the currently available dose.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Approval for Roche's SMA Drug & Other Updates

Teaser: FDA approves Roche's (RHHBY) new SMA drug, Evrysdi (risdiplam).

Novo Nordisk (NVO) Resumes Phase III Hemophilia Studies

Novo Nordisk (NVO) resumes the phase III studies on concizumabin in hemophilia A and B patients regardless of inhibitor status.

Novo Nordisk's (NVO) Q2 Earnings Beat Estimates, Sales Miss

Novo Nordisk's (NVO) earnings surpass estimates but revenues miss the same in the second quarter of 2020.

Novo Nordisk's Shares Rise on New Approvals, Strong Portfolio

Shares of Novo Nordisk (NVO) rally on solid product portfolio aided by new approvals.

Sheraz Mian headshot

Top Stock Reports for Alphabet, Merck & Medtronic

Today's Research Daily features new research reports on 16 major stocks, including Alphabet (GOOGL), Merck (MRK) and Medtronic (MDT).

Novo Nordisk Completes Two Studies on Obesity Candidate

Novo Nordisk (NVO) provides data from a monotherapy study and a combination study on AM833.

Merck's Steglatro Non-Inferior in Cardiovascular Outcomes Study

Merck's (MRK) type 2 diabetes drug, Steglatro, achieves primary endpoint of non-inferiority in major adverse CV events compared to placebo in a late-stage cardiovascular outcomes study.

Kinjel Shah headshot

Pharma Stock Roundup: Coronavirus Updates From ABBV, LLY, JNJ, FDA Approvals

J&J (JNJ), AbbVie (ABBV) and Lilly (LLY) make progress in coronavirus research efforts.

Sriparna Ghosal headshot

3 Diabetes Management Stocks in the Spotlight Amid Coronavirus

Amid the widespread pandemic crisis, the diabetes management sector continues to thrive on account of multiple positive developments